

Horizon 2020 UK Sweden partnering



Image
Coming
Soon

Start Date: Tue, 13 Nov 2018 00:00:00

GMT

End Date: Tue, 13 Nov 2018 23:59:00 GMT

Innovate UK is organising a partnering event focused on fostering and facilitating R&D project consortia for Horizon 2020 funded projects for call topic "BHC-07-2019 - Regenerative medicine: from new insights to new applications"; to take place in Stockholm on the 13 th November.

Event programme

Date: 13 November 2018, time: 10:00 – 15:30, with registration and coffee from 09:30.

Venue: Vinnova, Mäster Samuelsgatan 56, 101 58 Stockholm

The event, open to SMEs, larger companies, technology centres, universities and research organisations, will provide a platform for new translational research, commercial and technological collaborations, especially between UK and Swedish businesses and research organisations. We anticipate hosting approximately 60 participants from the UK, Sweden and neighbouring countries.

09.30 – Registrations & Coffee – Vinnova Head office

10.00 – Welcome and setting the scene for the event (Karin Aase - head of section EU-relations, Vinnova)

10.10 – Introduction & Eligibility of UK participants (Jerome de Barros – UK National Contact Point, Innovate UK)

10.20 – Introduction to BHC-07-2019 - Regenerative medicine: from new insights to new applications – web-based (Maria Pilar Aguar Fernandez, European commission, DG RTD Health)

11.00 – Overview of National initiatives in the UK (Tristan Pritchard-Meaker - Business Development Manager EU, Cell & Gene Therapy Catapult)

11.20 – Overview of National initiatives in Sweden, including CAMP Center for Advanced Medicinal Products (Prof. Mikael Wiberg, Professor in Informatics, Umeå University)

11.40 – Experience from previously funded Health projects in Horizon 2020

BOOSTB4: Boost Brittle Bones Before Birth (Cecilia Götherström, Associate Professor, Karolinska Institutet)

C0806: Regenerative treatment of complete Traumatic Spinal Cord injury with a surgical implantation of a biodegradable device with FGF1 and nerve grafts (Bioarctic Neuroscience AB)